证券代码：002399 证券简称：海普瑞 公告编号：2025-022 深圳市海普瑞药业集团股份有限公司 第六届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：7票同意、0票弃权、0票反对。 公司于2021年12月10日召开的第五届董事会第十五次会议审议通过，公司决 定使用H股募集资金1.05亿美元以逐层增资的方式向全资子公司天道医药（香港） 有限公司增资，用于欧盟及其他全球市场拓展销售及营销网络以及基础设施的建 设。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）第六届董事会第 十五次会议（以下简称"会议"）通知及议案于 2025 年 4 月 10 日以电子邮件的 形式发出，会议于 2025 年 4 月 24 日下午 14:00 在深圳市南山区松坪山朗山路 21 号会议室以现场与通讯相结合的方式召开。本次会议应参与表决董事 7 人，实际 参与表决董事 7 人，其中张平先生、吕川先生、黄鹏先生、易铭先生以通讯方式 参与表决。公司监事及高级管理人员列席会议，会议由公司董事长李锂先生主持。 本次会议 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,394,250,050.21, representing a 1.53% increase compared to CNY 1,373,251,921.93 in the same period last year[8] - Net profit attributable to shareholders for Q1 2025 was CNY 156,590,188.54, a 1.00% increase from CNY 155,040,262.39 year-on-year[8] - The net profit after deducting non-recurring gains and losses increased by 20.27% to CNY 188,891,082.26 from CNY 157,052,354.18 in the previous year[8] - The total operating profit for the current period is 178,980,342.21, a decrease of 9.4% from 196,847,737.66 in the previous period[34] - Net profit for the current period is 156,169,189.45, showing a slight increase of 1.0% compared to 154,597,836.94 in the previous period[34] - The company's net profit margin improved, with net profit for the period showing a significant recovery compared to the previous period, although specific figures were not disclosed[33] Cash Flow - The net cash flow from operating activities decreased by 38.21% to CNY 544,031,931.35, down from CNY 880,453,882.15 in the same period last year[8] - The cash flow from operating activities is 544,031,931.35, down 38.3% from 880,453,882.15 in the previous period[39] - The net cash flow from investing activities saw a significant decline of 297.07%, resulting in a negative cash flow of ¥257,551,999.87, mainly due to increased purchases of financial products[19] - The cash flow from investment activities shows a net outflow of 257,551,999.87, compared to a net inflow of 130,688,287.99 in the previous period[40] - The net cash flow from financing activities increased by 103.37% to ¥22,602,544.83, as the amounts borrowed and repaid remained relatively stable compared to the previous year[19] - Net cash flow from financing activities was $22,602,544.83, a significant improvement from a negative $670,833,066.44 in the previous period[41] Assets and Liabilities - Total assets at the end of the reporting period were CNY 17,545,801,889.02, reflecting a 1.17% increase from CNY 17,343,523,964.97 at the end of the previous year[8] - Total liabilities increased to CNY 5,205,766,284.88 from CNY 5,141,403,413.17, reflecting an increase of approximately 1.2%[31] - The equity attributable to shareholders increased by 1.14% to CNY 12,287,013,002.74 from CNY 12,148,672,778.24 year-on-year[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,367, with the largest shareholder, Shenzhen Lerun Technology Co., Ltd., holding 32.31% of shares[22] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Xiamen Jintian Soil Investment Partnership, holding 27.81%[22] - The largest shareholder, Shenzhen Lerun Technology Co., Ltd., has a total of 474,029,899 shares, while the second-largest holds 408,041,280 shares[23] - The company has not reported any changes in the participation of the top ten shareholders in margin trading or securities lending activities compared to the previous period[24] - There are no preferred shareholders or related changes reported in the current period[24] Investment and Expenses - The company reported a significant increase in investment income, rising by 132.79% to CNY 20,292,064.76 from a loss of CNY 61,890,173.43 in the previous year[17] - Research and development expenses were CNY 39,993,799.57, up from CNY 35,294,968.25, indicating an increase of about 19.2%[33] - The company experienced a 190.08% decrease in financial expenses, resulting in a gain of CNY 56,508,230.69 due to foreign exchange gains[17] - The deferred income increased by 65.95% to CNY 45,279,690.29, primarily due to government subsidies received during the reporting period[15] - The company reported a substantial increase in asset disposal income, which rose by 4404.34% to CNY 1,288,820.50 from CNY 28,612.85 in the previous year[17] Inventory and Receivables - Accounts receivable increased to CNY 1,382,358,370.19 from CNY 1,178,554,557.22, showing a rise of about 17.3%[28] - Inventory decreased to CNY 4,952,734,323.44 from CNY 5,393,947,174.38, a decline of approximately 8.2%[28] Cash and Equivalents - The company's cash and cash equivalents at the end of the period were CNY 2,000,842,827.21, up from CNY 1,689,041,495.34 at the beginning of the period, indicating a growth of approximately 18.4%[28] - The ending balance of cash and cash equivalents was $1,740,464,878.53, down from $2,108,383,601.96 in the prior period[41] - The net increase in cash and cash equivalents was $318,638,044.68, slightly lower than $342,738,890.08 in the previous period[41] Other Financial Metrics - The total comprehensive income for the current period is 137,915,052.34, a decrease of 8.1% from 150,135,056.48 in the previous period[36] - Basic and diluted earnings per share for the current period are both 0.1067, an increase from 0.1057 in the previous period[36] - The company recorded a foreign exchange loss of 47,399,165.67 in other comprehensive income, contrasting with a gain of 3,002,651.97 in the previous period[35] - The company received cash from sales of goods and services totaling 1,327,258,705.88, down 11.1% from 1,493,180,137.55 in the previous period[39] - The company reported a decrease in cash received from other operating activities to 47,510,298.94, down from 97,379,140.23 in the previous period[39] - The company’s net impairment loss on assets decreased significantly to 44,094.91 from 33,754,398.03 in the previous period[34] Audit and Reliability - The first quarter report was not audited, indicating potential limitations in financial reliability[42]

一、主要会计数据和财务指标 三、分红送配方案情况 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1067 | 0.1057 | 0.95 | 0.0453 | | 每股净资产（元） | 8.37 | 8.22 | 1.82 | 8.43 | | 每股公积金(元) | 4 | 4.33 | -7.62 | 3.99 | | 每股未分配利润(元) | 2.86 | 2.41 | 18.67 | 2.99 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 13.94 | 13.73 | 1.53 | 13.01 | | 净利润(亿元) | 1.57 | 1.55 | 1.29 | 0.67 | | 净资产收益率(%) | 1.28 | 1.29 | -0.78 | 0.54 | 本次公司不分配不转赠。 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 125360.0 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥1,394,250,050.21, representing a year-over-year increase of 1.53% compared to ¥1,373,251,921.93 in the same period last year[5]. - Net profit attributable to shareholders was ¥156,590,188.54, a slight increase of 1.00% from ¥155,040,262.39 in the previous year[5]. - The net profit after deducting non-recurring gains and losses increased by 20.27% to ¥188,891,082.26 from ¥157,052,354.18 year-over-year[5]. - Total operating revenue for the current period reached ¥1,394,250,050.21, an increase of 1.4% compared to ¥1,373,251,921.93 in the previous period[23]. - Net profit for the current period was ¥156,169,189.45, slightly higher than ¥154,597,836.94 from the previous period, indicating a growth of about 1%[24]. - Earnings per share (EPS) for the current period was ¥0.1067, compared to ¥0.1057 in the previous period, showing an increase of 0.9%[25]. Cash Flow - The net cash flow from operating activities decreased significantly by 38.21% to ¥544,031,931.35 from ¥880,453,882.15 in the same period last year[5]. - Cash inflow from operating activities totaled ¥1,501,965,061.54, a decrease from ¥1,664,646,503.27 in the previous period, representing a decline of approximately 9.7%[26]. - The net cash flow from operating activities was $544,031,931.35, a decrease of 38.2% compared to $880,453,882.15 in the previous period[27]. - Total cash outflow from operating activities amounted to $957,933,130.19, up from $784,192,621.12, indicating a 22.1% increase[27]. - Cash inflow from investment activities totaled $605,376,122.24, compared to $441,112,963.21, reflecting a 37.3% increase[27]. - The net cash flow from investment activities was -$257,551,999.87, a decline from $130,688,287.99 in the previous period[27]. - Cash inflow from financing activities was $750,396,287.53, down from $835,834,333.10, representing a decrease of 10.2%[27]. - The net cash flow from financing activities was $22,602,544.83, a significant improvement from -$670,833,066.44 in the previous period[27]. - The total cash and cash equivalents at the end of the period were $1,740,464,878.53, down from $2,108,383,601.96[27]. - The cash and cash equivalents increased by $318,638,044.68 during the period, compared to an increase of $342,738,890.08 in the previous period[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥17,545,801,889.02, reflecting a 1.17% increase from ¥17,343,523,964.97 at the end of the previous year[5]. - The company's total liabilities amounted to ¥5,205,766,284.88, compared to ¥5,141,403,413.17 in the previous period, reflecting an increase of about 1.25%[21]. - Total equity attributable to shareholders reached ¥12,287,013,002.74, up from ¥12,148,672,778.24, marking an increase of approximately 1.14%[21]. - Total current assets amount to 9,873,944,183.93 RMB, an increase from 9,621,274,306.15 RMB at the beginning of the period[19]. - Total assets amount to 17,545,801,889.02 RMB, compared to 17,343,523,964.97 RMB at the beginning of the period[20]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 28,367[16]. - The largest shareholder, Shenzhen Lerun Technology Co., Ltd., holds 32.31% of shares, totaling 474,029,899 shares[16]. - The second-largest shareholder, Xiamen Jintian Investment Partnership, holds 27.81%, totaling 408,041,280 shares[16]. Other Financial Metrics - The company's basic earnings per share (EPS) was ¥0.1067, up 0.95% from ¥0.1057 in the same period last year[5]. - The weighted average return on equity (ROE) slightly decreased to 1.28% from 1.29% year-over-year[5]. - The company reported a decrease in financial expenses, with a net financial cost of -¥56,508,230.69 compared to ¥62,732,180.93 in the previous period[24]. - The company experienced a decrease in comprehensive income, totaling ¥137,915,052.34 compared to ¥150,135,056.48 in the previous period, a decline of about 8%[25]. - The company reported a significant increase in deferred income by 65.95% to ¥45,279,690.29 due to government subsidies received during the reporting period[11]. - Deferred income increased to ¥45,279,690.29 from ¥27,284,974.87, indicating a significant rise of approximately 65.9%[21]. - The company has a total of 366,727,264.95 RMB in long-term equity investments[20]. - The company’s goodwill stands at 2,353,689,028.00 RMB, a slight decrease from 2,357,033,547.26 RMB[20]. - Inventory decreased to 4,952,734,323.44 RMB from 5,393,947,174.38 RMB[20]. - Short-term borrowings are reported at 1,819,531,746.74 RMB, slightly down from 1,838,944,224.03 RMB[20]. - The company paid $225,883,127.82 to employees, an increase from $182,063,990.65 in the previous period[27]. - The company reported a total tax payment of $71,329,471.04, up from $61,136,636.42, indicating a 19.8% increase[27].

Core Viewpoint - The approval of Ivenoxin (enoxaparin sodium injection) by the South African Health Products Regulatory Authority is expected to enhance the sales of the product in the South African market and increase the company's global market share [1] Company Summary - The company, Haiprui (002399), announced that its wholly-owned subsidiary, Tiandao Pharmaceutical, has received the approval notification for enoxaparin sodium injection [1] - The product is available in various specifications: 0.2ml:20mg, 0.4ml:40mg, 0.6ml:60mg, 0.8ml:80mg, and 1.0ml:100mg [1] - The indications for the product include thrombosis prevention before and after surgery, reduction of thrombotic risk in acute diseases, and treatment of deep vein thrombosis [1] - The license for the product is valid for five years [1] Industry Summary - The approval is anticipated to boost the company's enoxaparin sodium formulation sales in South Africa, contributing positively to its market presence [1]

证券代码：002399 证券简称：海普瑞 公告编号：2025-021 根据外部市场环境结合公司全球业务发展的需求，经公司于2025年4月24日 召开的第六届董事会第十五次会议审议通过，决定对原增资方案进行调整，将原 增资金额1.05亿美元调整为3,192万美元，其余内容不变。 调整后的增资金额在公司董事会决策权限内，无需提交股东大会审议批准。 上述调整增资方案的事项不构成关联交易，亦不构成《上市公司重大资产重组管 理办法》规定的重大资产重组。 一、增资标的的基本情况 （一）多普乐 关于向全资子公司天道医药（香港）有限公司增资 的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示 经深圳市海普瑞药业集团股份有限公司（以下简称"公司"或"海普瑞"） 于2021年12月10日召开的第五届董事会第十五次会议审议通过，公司决定使用H 股募集资金1.05亿美元以逐层增资的方式向全资子公司天道医药（香港）有限公 司（以下简称"香港天道"）增资，用于欧盟及其他全球市场拓展销售及营销网 络以及基础设施的建设。具体增资路径为海普瑞向其全资子公司深圳市多普乐实 ...

深圳市海普瑞药业集团股份有限公司（以下简称"公司"）的全资孙公司深圳 市天道医药有限公司（以下简称"天道医药"）近期收到南非卫生产品管理局（South African Health Products Regulatory Authority）签发的依诺肝素钠注射液批准通知。 现将相关情况公告如下： （五）适应症： （六）许可有效期：五年 证券代码： 002399 证券简称：海普瑞 公告编号：2025-024 深圳市海普瑞药业集团股份有限公司 关于依诺肝素钠注射液获得南非药品注册批件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、基本情况 《证券时报》《证券日报》《中国证券报》《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）为公司指定信息披露媒体，公司所有信息均以在上述指定媒 体刊登的信息为准。公司将严格按照有关法律法规的规定和要求，认真履行信息披 露义务，及时做好信息披露工作。 公司郑重提请投资者注意：投资者应充分了解股票市场风险及公司定期报告 中披露的风险因素，审慎决策、理性投资。 特此公告 深圳市海普瑞药业集团股份有限公司 二 ...

| ○ 基金经理:马君 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 累计任职时间：12年又220天 任职起始日期：2012-09-04 现任基金公司：银华基金管理股份有限公司 现任基金资产 在管基金量佳 息规模 | 任期回报 | | 基金经理简介:马君女士:硕士学位。2008年7月至2009年3月任职大成基金管理有限公司助 理金融工程师。2009年3月加盟银华基金管理有限公司,曾担任研究员及基金经理助理职务。 自2012年9月4日至2020年11月30日担任银华中证内地资源主题指数分级证券投资基金基金经 理,2013年12月16日至2015年7月16日兼任银华消费主题分级混合型证券投资基金基金经 理,2015年8月6日至2016年8月5日兼任银华中证国防安全指数分级证券投资基金基金经 理,2015年8月13日至2016年8月5日兼任银华中证一带一路主题指数分级证券投资基金基金经 | | | | | | 337.41亿元 13.17% | | | | | | | | 马君 | | | | 理,自2016年1月14日至 ...

证券代码：002399 证券简称：海普瑞 深圳市海普瑞药业集团股份有限公司 投资者关系活动记录表 编号：2025-001 5.公司站在当下，公司目前最新的战略是什么？如何看待公司的制剂、 原料药、CDMO，创新药这几块业务的发展与平衡？25年公司估计会有什么 业务的亮点和让人惊喜的地方？ 答:2025年，海普瑞将持续坚持稳中求进的策略，聚焦全球化布局和高质 量发展，主要分为五个方面：（1）强化全球供应链布局，灵活应对贸易环境 转变，创造竞争优势，巩固在肝素领域的核心竞争力。（2）积极拓展国际市 场，挖掘新兴市场潜力，优化全球销售网络，提升渗透率和市场份额。（3） 持续推动CDMO业务的扩展，提升服务水平，进一步巩固竞争力，创造新增 长点。（4）全力推进H1710后续研发和临床工作。（5）持续提升财务管理能 力，确保现金流稳健，提升资本使用效率。谢谢！ 6.2024年扣非净利润受投资端减值、联营企业投资亏损等因素扰动较多， 请问：1、大约影响了24年多少利润? 2、25年影响利润的幅度相比24年是多 还是少？估计25年影响大约多少？ 答:您好，详细数据请参阅公司发布的《2024年年度报告》，2025年公司 将继 ...

Core Viewpoint - The company has reported a turnaround in profitability, achieving a net profit of 647 million RMB in 2024, compared to a loss of 783 million RMB in the previous year, primarily driven by the recovery in CDMO business demand and improved management efficiency [2] Group 1: Financial Performance - The company achieved operating revenue of 5.281 billion RMB in 2024, a year-on-year decrease of 3.03% [2] - The CDMO business generated revenue of 1.034 billion RMB with a gross margin of 35.83%, reflecting a year-on-year increase of 13.8 percentage points [2] - Non-recurring gains included approximately 267 million RMB from the disposal of equity in Junshengtai and 202 million RMB from changes in fair value of financial products [2] Group 2: Business Operations - The company’s heparin API business is produced and sold locally in the U.S. by a wholly-owned subsidiary, thus not affected by U.S. tariffs [1][6] - The heparin product sales in the European market remain strong, with the company maintaining a top two market share [6] - The company has expanded its market presence in non-European and non-American regions, achieving significant sales growth in countries like Thailand, New Zealand, and Argentina [6] Group 3: Market Challenges - The heparin raw material business saw a revenue decline of 18.23% year-on-year, despite a 10.82% increase in sales volume, due to intense market competition leading to lower prices [4] - The overall revenue from the heparin industry chain decreased by 5.40% year-on-year, with the formulation segment achieving a slight revenue increase of 0.24% [4] - The company faces challenges in maintaining gross margins due to significant price reductions in the Chinese market driven by centralized procurement [5]